Technical Data
EBI3 (Interleukin-27 Subunit beta, IL-27 Subunit beta, IL-27B, Epstein-Barr Virus-induced Gene 3 Protein, EBV-induced Gene 3 Protein, IL27B)
EBI3 is a 228aa containing pro- and anti-inflammatory cytokine belonging to the type I cytokine receptor family and contains two fibronectin type-III domain. It forms a heterodimer with IL-27 and is also a component of the IL-12 heterodimer. A protein involved in regulated cell-mediated immune responses, EBI3 has an important role in regulating T helper cell development, suppressing T-cell proliferation, stimulating cytotoxic T-cell activity, inducing isotype switching in B-cells, and has diverse effects on innate immune cells. Target cells of EBI3 include CD4 T helper cells, type 1 effector cells (TH1), type 2 effector cells (TH2) and IL-17 producing helper T-cells (TH17). It drives rapid clonal expansion of naive but not memory CD4 T-cells. EBI3 is important in anti-tumor as well as anti-angiogenic activity with activation and production of anti-angiogenic chemokines. It also strongly synergizes with IL-12 to trigger interferon-gamma:IFN-gamma production of naive CD4 T-cells.

Suitable for use in Western Blot and Immunohistochemistry. Other applications not tested.

Recommended Dilution:
Western Blot: 0.5-2ug/ml
Immunohistochemistry (formalin fixed paraffin embedded): 5ug/ml
Optimal dilutions to be determined by the researcher.

Storage and Stability:
May be stored at 4C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20C. Aliquots are stable for at least 12 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
PabIgGAffinity Purified
100ug-20CBlue IceMouseRabbit
Synthetic peptide corresponding to aa200-230 of mouse EBI3.
Purified by immunoaffinity chromatography.
Supplied as a liquid in PBS, 0.05% BSA, 0.05% sodium azide.
Recognizes mouse EBI3. Species Crossreactivity: rat.
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.
1. Batten, M. et al. J. Mol. Med. 85:661-672 (2007).